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Abstract
Background: Microvascular ischemia is one of the hallmarks of hypertrophic cardiomyopathy (HCM) and has been
associated with poor outcome. However, myocardial fibrosis, seen on cardiovascular magnetic resonance (CMR) as
late gadolinium enhancement (LGE), can be responsible for rest perfusion defects in up to 30 % of patients
with HCM, potentially leading to an overestimation of the ischemic burden. We investigated the effect of left
ventricle (LV) scar on the total LV ischemic burden using novel high-resolution perfusion analysis techniques
in conjunction with LGE quantification.
Methods: 30 patients with HCM and unobstructed epicardial coronary arteries underwent CMR with Fermi
constrained quantitative perfusion analysis on segmental and high-resolution data. The latter were corrected
for the presence of fibrosis on a pixel-by-pixel basis.
Results: High-resolution quantification proved more sensitive for the detection of microvascular ischemia in
comparison to segmental analysis. Areas of LGE were associated with significant reduction of myocardial perfusion
reserve (MPR) leading to an overestimation of the total ischemic burden on non-corrected perfusion maps. Using a
threshold MPR of 1.5, the presence of LGE caused an overestimation of the ischemic burden of 28 %. The ischemic
burden was more severe in patients with fibrosis, also after correction of the perfusion maps, in keeping with more
severe disease in this subgroup.
Conclusions: LGE is an important confounder in the assessment of the ischemic burden in patients with HCM.
High-resolution quantitative analysis with LGE correction enables the independent evaluation of microvascular
ischemia and fibrosis and should be used when evaluating patients with HCM.
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enhancement, Cardiovascular magnetic resonance
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Background
Hypertrophic cardiomyopathy (HCM) is the most
common genetic cardiomyopathy [1]. While the ma-
jority of patients remain asymptomatic, in a subset
of patients the prognosis is poor with progression to
heart failure or presentation with sudden cardiac
death (SCD) [2–4]. HCM is considered the most
common cause of SCD in young competitive athletes
[5, 6].
The hallmarks of the disease include left ventricle
(LV) hypertrophy, fibrosis and microvascular ischemia
[7] and it remains debated as to whether there is a
causative link between these features [8]. Microvascular
ischemia can be diagnosed using non-invasive imaging
modalities, including positron emission tomography
(PET) [7], single photon emission computed tomog-
raphy (SPECT) [9] and first-pass perfusion cardiovascu-
lar magnetic resonance (CMR) [10, 11]. CMR is
emerging as the imaging modality of choice for HCM
due to its unrivalled capability to assess LV hypertrophy
and LV fibrosis. Alongside structural changes, CMR can
also assess the presence of ischemia within a single
examination. To date however, only two studies have
used CMR to evaluate the relationship between LV
hypertrophy, fibrosis and perfusion [10, 12]. The study
from Petersen et al. [10] used segmental quantitative
perfusion analysis, while Ismail et al. [12] demonstrated
the feasibility of high-resolution perfusion quantification
in patients with HCM. Both studies proved a close
relationship between the severity of microvascular is-
chemia, the degree of hypertrophy and the severity of
LV fibrosis in keeping with previous studies that used
PET [7, 13, 14], or a combination of PET and CMR
[15]. However, no studies have specifically explored
the impact of late gadolinium enhancement (LGE) on
perfusion analysis in HCM. This is of particular rele-
vance since LGE is observed in 60-80 % of patients
and is frequently associated with rest perfusion abnor-
malities [16–19].
High-resolution quantification of perfusion CMR has
been shown to provide accurate perfusion estimates
[20, 21] and, in contrast to segmental quantification,
preserves the spatial resolution of the original imaging
data, potentially resulting in a more sensitive detection
of microvascular ischemia [12]. Another possible and
yet unexplored advantage of high-resolution perfusion
quantification is the possibility to combine the interpret-
ation of quantitative perfusion results in conjunction
with the results of LV scar analysis on a high-resolution
level.
The aim of this study is to demonstrate the feasibility
of combined high-resolution quantitative perfusion and
LGE analysis. Specifically, we aimed to determine the ef-
fect of overt LV scar on the total LV ischemic burden.
Methods
Consecutive patients with a clinical diagnosis of HCM
and visually unobstructed or with minor non-obstructive
atheroma (30 % visual stenosis or less) on invasive cor-
onary angiography referred for perfusion CMR were
retrospectively identified. The diagnosis of HCM was
based on confirmation from genetic testing or on con-
ventional criteria for HCM diagnosis (presence of a wall
thickness ≥ 15 mm, or 13 mm in patients with family
history of HCM, without chamber dilation and in the
absence of any other systemic or cardiac disease suffi-
cient to justify the hypertrophy). Patients had been
scanned on clinical grounds at St. Thomas’ Hospital,
London. All patients gave written and informed consent
at the time of the scan (ethics committee approval 15/
NS/0030). This study was performed in accordance with
the principles of the Declaration of Helsinki.
Scans were performed at 3.0 T (Philips Achieva-TX,
Philips Medical Systems) and included myocardial
function, stress and rest perfusion and late gadolin-
ium enhancement imaging using standard acquisition
protocols [22]. A 32-channel cardiac phased array re-
ceiver coil was used for all studies.
The perfusion sequences were performed during
adenosine-induced hyperemia over 3 min (140 μg/kg/min)
and repeated 15 min later at rest, both times using
0.075 mmol/kg gadobutrol (Gadovist, Bayer, Berlin,
Germany) at 4 ml/s followed by a 20 ml saline flush. A
dual bolus protocol for contrast agent injection was used
as previously described [23]. All subjects were asked to ab-
stain from caffeine and caffeine-containing food and
drinks for at least 24 hours before the scan, according to
institutional practice.
First-pass perfusion imaging consisted of a high-
resolution kt turbo-gradient echo sequence [typical im-
aging parameters: shortest echo time (range 1.35–1.54 ms),
shortest repetition time (range 2.64–3.12 ms), 18° flip
angle, 90° saturation prepulse, 120 ms prepulse delay,
typical TR 2.6 ms, typical TE 0.9 ms, typical spatial
resolution 1.2x1.2x10mm)]. Three short-axis slices
(basal, mid and apical) were acquired over every heart-
beat covering 16 of the standard myocardial segments
(segment 17 was excluded). A correction map was cre-
ated from a proton density-based image based on the
same projections as the perfusion scans for correction
of spatial inhomogeneities due to surface coils [24].
LGE imaging was acquired after a top up dose of con-
trast agent to a total dose of 0.2 mmol of gadolinium/
kg of body weight, according to standard acquisition
methods [22].
Image analysis
Image analysis was performed according to standard
practice [25]. Perfusion series were evaluated visually for
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the presence or absence of perfusion abnormalities.
Quantitative perfusion analysis was performed both on a
segmental and high-resolution basis. High-resolution re-
sults were evaluated with and without inclusion of re-
gions with overt LGE, identified using a standard
threshold-based approach as detailed below.
Standard evaluation of the left ventricle
LV function, global LV mass and maximal segmental LV
wall thickness were analyzed using commercially avail-
able software (CVI42, version 4.1.8, Circle Cardiovascu-
lar Imaging Inc., Calgary, Alberta, Canada) according to
standardized methods [25]. All the indices were cor-
rected for body surface area. Hypertrophy was defined
by an end-diastolic wall thickness equal or greater than
15 mm [1].
Two independent observers judged the presence of fi-
brosis visually and recorded LGE in terms of standard
LV segments. Using commercially-available software, ac-
cording to standardized methods, areas of scar were
measured [26] (CVI42, version 4.1.8, Circle Cardiovascu-
lar Imaging Inc., Calgary, Alberta, Canada). A threshold
of six standard deviations above the average signal of a
remote and non-enhanced region was used to define
overt scar [26].
Visual perfusion assessment
Perfusion data were assessed visually by two operators
by consensus and abnormalities recorded in terms of
standard LV segments. Perfusion abnormalities were de-
fined as a visual reduction in the signal intensity (SI) of
an area of myocardium lasting longer than five cardiac
cycles and not related to obvious respiratory, motion or
dark rim artifact.
Perfusion abnormalities were classified visually in
three categories: 1) subendocardial perfusion abnormal-
ities, seen as a gradient of reduced perfusion arising
from the subendocardium in absence of LGE in the
same segment; 2) LGE-related perfusion abnormalities,
seen only in the mid-myocardial layers and exclusively
in correspondence with overt, confluent areas of LGE; 3)
mixed perfusion abnormalities, in segments where both
LGE-related and subendocardial perfusion abnormalities
were observed.
Quantitative perfusion analysis
Two experienced operators, blinded to results of visual
perfusion assessment and other clinical data, performed
quantitative analysis using software and methods devel-
oped and previously validated by our group against perfu-
sion phantom, PET data and microspheres [21, 27, 28].
Quantitative signal intensity (SI) analysis required accur-
ate respiratory motion correction and myocardial contour
delineation. Respiratory motion was corrected using affine
image registration by maximization of the joint correlation
between consecutive dynamics within an automatically
determined region of interest. A temporal maximum in-
tensity projection was calculated to serve as a feature
image for an automatic contour delineation method. The
operator then manually optimized the automatically gen-
erated contours to avoid partial volume effects at the
endocardial and epicardial border as previously described
[29]. Areas of subendocardial dark-rim artifact occurring
at the arrival of the main bolus of contrast agent in the LV
were carefully excluded from the segmentation.
Segmental quantitative perfusion analysis was per-
formed using spatially averaged myocardial SI curves ac-
cording to standard cardiac segmentation [30].
Quantitative perfusion analysis was performed by
Fermi deconvolution according to the methods de-
scribed by Wilke et al. [31] and Jerosch-Herold et al.
[32] where time curves for the tissue impulse response
function, h(t), were fitted to the Fermi function with the
following analytical expression:
h tð Þ ¼ R 1
e t−τ0−τdð Þk þ 1
 
u t−τdð Þ
using a Marquardt-Levenberg nonlinear least square al-
gorithm by letting k, R and τ0 vary and keeping τd fixed.
In the above equation, u(t − τd) is the unit step function.
The τd accounts for the delay time between the appear-
ance of the signal in the LV blood pool and myocardial
region of interest (ROI) [33] τ0 characterizes the width
of the shoulder of the Fermi function during which little
or no contrast agent had left the ROI. R is the index of
contrast agent influx parameter and k represents the
decay rate of h(t) due to contrast agent washout. Using
the above equation, myocardial blood flow (MBF) esti-
mates are calculated as h(t) at t = 0 [32].
Myocardial perfusion reserve (MPR) was calculated as
the ratio between stress and rest MBF estimates.
Combined high-resolution fibrosis and perfusion
quantification
Current two-dimensional perfusion techniques involve
each slice being acquired in a different phase of the
cardiac cycle while LGE is acquired in a pre-specified
phase, usually in end-diastole. Therefore, prior to any
quantification, the LGE and perfusion images had to
be registered. Firstly an LGE slice was selected that
matched the corresponding perfusion slice in terms of
position within the LV. A pair of endocardial and epi-
cardial LV contours were then drawn on rest and
stress perfusion and LGE images and a deformable
template segmentation method was applied to the im-
ages and optimized using a greedy optimization
scheme as previously described [29].
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High-resolution quantitative MPR and fibrosis maps
were generated allowing generation of high-resolution
MPR maps and calculation of the ischemic burden
with and without inclusion of areas of overt myocar-
dial scar (Fig. 1).
Total ischemic burden calculation
In order to represent and compare total ischemic burden
measurements obtained using segmental and high-
resolution quantitative analysis, we adopted the methods
described and recommended by the ISCHEMIA Trial
expert panel to compare ischemic burden measurements
obtained by different imaging modalities [34]. In brief,
the ischemic burden was expressed as percentage of LV
myocardium for different MPR values for both segmen-
tal and high-resolution results.
Statistical analysis
Categorical data are presented as numbers and per-
centages and continuous data are presented as mean
± standard deviation (SD). The normal distribution of
high-resolution MPR estimated was tested with P-P
plot and a skewness test. Group means were com-
pared using an unpaired Student t test and categorical
data were compared between groups using the Fisher
exact test and Pearson chi-square test, as appropriate.
Values of p < 0.05 was considered to be statistically sig-
nificant. ANOVA was used to determine differences be-
tween multiple groups. Bonferroni correction was used to
account for multiple testing in both segmental and high-
resolution quantitative perfusion analysis. Bland-Altman
and Pearson’s analysis were used to assess the interopera-
tor reproducibility of the ischemic burden measurements.
Results
The study cohort comprised 30 patients (77 % male, age
range 61 ± 13 years). Demographics of patients are
shown in Table 1.
Standard evaluation of the left ventricle
Structural and functional CMR findings and hemodynamic
parameters are also shown in Table 1. The average number
of hypertrophic segments was 3.1 ± 2.6 per patient (range
1–11 segments per patient). Maximum LV wall thickness
was >25 mm in 2/30 patients (6 %) and >20 mm in 7/30
patients (23 %). 21/30 patients (70 %) were positive for LV
fibrosis, most frequently involving the septal segments.
Detailed segmental results of hypertrophy, fibrosis and
perfusion are summarized in Fig. 2.
Visual perfusion assessment
Stress-induced perfusion abnormalities (either suben-
docardial or mixed) were found in 18/30 (60 %) pa-
tients on visual assessment involving 185/304 (61 %)
segments amongst positive patients. Subendocardial
perfusion abnormalities were seen in 14/30 (47 %) pa-
tients and 4/30 (13 %) patients had mixed perfusion
abnormalities. 1/30 (3 %) patient had only scar-related
perfusion abnormalities. 11/30 (37 %) patients had
visually normal perfusion.
No association was observed between average wall
thickness of hypertrophic segments and perfusion ab-
normalities (wall thickness was 16.8 ± 2.1 mm for seg-
ments with subendocardial perfusion abnormalities,
15.5 ± 0.7 mm for LGE-related perfusion abnormal-
ities, and 17.6 ± 2.7 mm for mixed perfusion abnor-
malities; p = 0.38).
Fig. 1 Example of combined high-resolution fibrosis and perfusion mapping. a-c late gadolinium enhancement (LGE) images. d-f stress perfusion
images. Top, middle and bottom rows correspond with basal, mid and apical slices respectively. Images (g) and (h) indicate high-resolution
maps for LGE and stress perfusion respectively (basal slice only), with the grid used for high-resolution maps of LGE (I) and stress perfusion (J)
shown below
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Segmental quantitative perfusion
Using segmental quantitative analysis, segments with
visual perfusion abnormalities and LGE (PERF + LGE+)
had the lowest MPR values (2.2 ± 0.5). Conversely, seg-
ments negative for visual perfusion abnormalities and LGE
(PERF-LGE-) had the highest MPR values (2.6 ± 0.6). Seg-
ments with visual perfusion abnormalities, but no LGE
(PERF + LGE-) had MPR values of 2.3 ± 0.5. Segments
with LGE and visually normal perfusion (PERF-LGE+)
had MPR values of 2.4 ± 0.5. A significant difference
was observed between PERF + LGE+ versus PERF-
LGE- (p < 0.0001) and PERF + LGE- versus PERF-LGE-
(p < 0.0001). Detailed results are presented in Fig. 3.
High-resolution perfusion quantification
On high-resolution perfusion quantification, PERF +
LGE+ regions had the lowest MPR values (1.8 ± 0.7).
PERF-LGE- regions had the highest MPR values (2.5 ±
0.9). PERF + LGE- regions had MPR values of 2.1 ± 1.
PERF-LGE+ regions had MPR values of 2.0 ± 0.8. A sig-
nificant difference was observed between all categories
(p < 0.0001).
Comparing high-resolution and segmental perfusion
quantification results, high-resolution measured signifi-
cantly lower MPR values in all groups with the excep-
tion of PERF-LGE-. Detailed results are also presented
in Fig. 3.
Ischemic burden measurements
Total LV ischemic burden for segmental and uncorrected
high-resolution perfusion quantification are shown in
Table 1 Baseline characteristics of the patients and cardiac magnetic resonance (CMR) functional results. Patients are classified
according to the results of perfusion (PERF) and late gadolinium enhancement (LGE) visual assessment as four groups: PERF + LGE+
(perfusion abnormality positive, LGE positive), PERF + LGE- (perfusion abnormality positive, LGE negative), PERF-LGE+ (perfusion
abnormality negative, LGE positive) and PERF-LGE- (perfusion abnormality negative, LGE negative)
All (N = 30) PERF + LGE+ (N = 12) PERF + LGE- (N = 7) PERF-LGE+ (N = 9) PERF-LGE- (N = 2)
Male gender 23 (77 %) 11 (92 %) 5 (71 %) 6 (67 %) 1 (50 %)
Age (years) 61 ± 13 61 ± 10 52 ± 13 65 ± 13 76 ± 13
LA (cm2) 23.1 ± 5.6 22.9 ± 4.8 21.3 ± 2.6 22.4 ± 6.9 33.5 ± 0.7
RA (cm2) 20 ± 4.1 20.8 ± 4.4 19.6 ± 2.4 19.3 ± 4.6 20 ± 7.1
LV EF (%) 64.8 ± 10 68.1 ± 7 69.4 ± 5.8 57.4 ± 11.1 62.5 ± 20.5
LV EDV index (ml/m2) 71.9 ± 23.2 73.5 ± 20.4 63.3 ± 11.5 71.1 ± 23.9 95.5 ± 63.4
LV ESV index (ml/m2) 26.5 ± 15.7 24 ± 9.5 19.5 ± 5.6 31.8 ± 19.1 42.3 ± 42.7
LV mass index (g/m2) 82.7 ± 32.8 93.7 ± 38.4 65.6 ± 23 80 ± 27.6 86.4 ± 43.4
RV EF (%) 66.7 ± 8.1 69.8 ± 8.8 64.9 ± 7.4 57.4 ± 11.1 61 ± 4.2
RV EDV index (ml/m2) 65.3 ± 17.6 68.2 ± 21.9 63.7 ± 9.8 59.8 ± 9.9 79.2 ± 40
RV ESV index (ml/m2) 22.4 ± 8.3 21.5 ± 10.7 22.3 ± 5.4 22.1 ± 5.9 30 ± 12.3
Max LV thickness (mm) 25 25 19 20 21
Average LV thickness (mm) 10.5 ± 4 11.3 ± 4.4 9.4 ± 3.3 10.3 ± 4 10.5 ± 3.3
Hypertrophic segments/patient 3.1 ± 2.6 4.3 ± 3.1 1.4 ± 1.1 3 ± 2.3 1.5 ± 0.7
LGE % 7.3 ± 7.4 11.5 ± 8.4 0.7 ± 0.8 8.2 ± 4.6 0.5 ± 0.7
HR (bpm)
- Rest 72 ± 12 75 ± 12 76 ± 13 66 ± 11 63 ± 11
- Stress 94 ± 10 96 ± 12 96 ± 6 90 ± 11 87 ± 11
BP (mmHg)
- Rest 135 ± 14/91 ± 10 140 ± 16/78 ± 13 129 ± 9/80 ± 7 135 ± 14/83 ± 6 130 ± 14/88 ± 9
- Stress 132 ± 20/78 ± 12 137 ± 19/77 ± 12 128 ± 22/80 ± 13 129 ± 20/75 ± 7 132 ± 39/88 ± 22
PERF perfusion abnormalities, LGE late gadolinium enhancement, LA left atrium, RA right atrium, LV left ventricle, EF ejection fraction, EDV end-diastolic volume,
ESV end-systolic volume, RV right ventricle, LGE: late gadolinium enhancement HR heart rate, BP blood pressure
Fig. 2 Schematic representation of the distribution of hypertrophic
segments, late gadolinium enhancement (LGE) and perfusion
abnormalities based on visual assessment, expressed as percentages of
the total cohort
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Fig. 4. High-resolution quantification proved more sensi-
tive to the detection of myocardial ischemia in compari-
son with segmental analysis, with larger ischemic burden
detected at all MPR thresholds (p < 0.001).
The LV ischemic burden on high-resolution quanti-
fication in LGE+ and LGE- patients is shown in Fig. 5.
For LGE+ patients, both corrected and uncorrected
ischemic burden percentages are shown. LGE+ pa-
tients had a significantly higher ischemic burden in
comparison to LGE- patients at all considered MPR
thresholds (p = 0.01). Correction of the results by ex-
clusion of regions with overt LGE caused a significant
reduction of the measured ischemic burden at all
thresholds (p = 0.04). Despite this adjustment however,
LGE+ patients had a higher ischemic burden in com-
parison to LGE- patients for all MPR thresholds
above 1.3 (p = 0.04). In order to examine the effect of
overt LGE on measured ischemic burden at different
Fig. 3 Comparison between myocardial perfusion reserve (MPR) values obtained by using segmental and high-resolution quantification. Regions
are classified according to the results of perfusion (PERF) and late gadolinium enhancement (LGE) visual assessment. *p < 0.0001 vs. segmental
MPR of PERF-LGE- regions; † p < 0.0001 vs. all other groups for high-resolution MPR
Fig. 4 Correlation between the different myocardial perfusion reserve (MPR) thresholds and the percentage of ischemic burden for segmental
and high-resolution perfusion quantification
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MPR thresholds, the percentage difference (or relative
error) of ischemic burden between corrected and non-
corrected high-resolution perfusion maps was calculated,
using uncorrected results as the normalization factor
(Fig. 6). The relative error in ischemic burden measure-
ments increased steeply between an MPR threshold of 0.5
and 1 (relative error 4.3 and 22 %, respectively), increased
at a slower rate between an MPR of 1 and 1.5 (relative
error 27.7 %) and was stable or slightly decreased for
MPR > 1.5. The comparison between uncorrected and
corrected ischemic burden per patient is shown in Fig. 7.
The patients were grouped by tertiles of ischemic bur-
den before correction by LGE (lowest ischemic burden
0–4.7 %; intermediate ischemic burden 4.8–12.8 %;
highest ischemic burden 12.9–24 %). When results
were corrected by the presence of LGE, a total of 9/30
patients (30 %) were recategorised to a lower tertile of
ischemic burden. Specifically, 4 patients were re-
classified from the intermediate ischemic burden group
to the lowest ischemic burden group; 2 patients were
Fig. 5 Correlation between the different myocardial perfusion reserve (MPR) thresholds and percentage of ischemic burden for high-resolution
perfusion quantification of patients with a visual perfusion abnormality with and without including areas with overt late gadolinium enhancement
(LGE), and in patients without LGE
Fig. 6 Correlation between the different myocardial perfusion reserve (MPR) thresholds and relative error due to the inclusion of overt scar in the
high-resolution perfusion analysis LGE: late gadolinium enhancement
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re-classified from the highest ischemic burden group to
the lowest ischemic burden group; 3 patients were re-
classified from the highest ischemic burden group to
the intermediate ischemic burden group.
Corrected ischemic burden proved to be robust to
inter-observer variability of LGE measurements. Repro-
ducibility results are shown in Fig. 8 for a MPR of 1.5.
Discussion
The main findings of this study are: 1) combined CMR
high-resolution quantitative assessment of myocardial per-
fusion and LV fibrosis is feasible in patients with HCM; 2)
high-resolution quantitative perfusion assessment pre-
serves the resolution of the original imaging data, is more
sensitive than segmental quantitative analysis for ischemia
and allows for correction of perfusion data for LGE; 3) LV
scar has a significant confounding effect on ischemic bur-
den measurements; 4) 30 % of patients are re-classified to
a lower tertile of ischemic burden if high-resolution perfu-
sion maps are corrected by LV scar; 5) patients with LGE
have larger ischemic burden in comparison with patients
without LGE. This difference is maintained also after cor-
rection of high-resolution perfusion maps by LV scar, pos-
sibly indicating more severe disease.
Fig. 7 a Non-corrected and corrected ischemic burden. Individual cases and average and standard deviation are shown. b Tertiles of non-corrected
high-resolution ischemic burden and recategorization after correction for late gadolinium enhancement (LGE)
Fig. 8 Impact of the inter-observer variability of late gadolinium enhancement (LGE) analysis on corrected ischemic burden measurements.
a Pearson’s analysis. b Bland-Altman graph LGE: late gadolinium enhancement
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Microvascular dysfunction is an important feature of
HCM and can be diagnosed non-invasively by stress per-
fusion CMR [10, 12], where “perfusion abnormalities”
have been interpreted as a surrogate marker of micro-
vascular ischemia. This is thought to be an independent
predictor for the development of LV dysfunction, LV ad-
verse remodelling and adverse prognosis [8].
High-resolution perfusion CMR quantification has
been proposed as an accurate method to assess micro-
vascular ischemia in patients with HCM. Despite the
lower signal-to-noise ratio, high-resolution perfusion
CMR quantification is capable of very accurate estimates
of MPR, as demonstrated previously by our group and
by others [20, 21, 35, 36].
Current results confirm the feasibility of this approach
and demonstrate the potential to perform a combined
assessment of quantitative perfusion and LGE maps and
measure the effect of the presence of overt scar on non-
invasive measurements of ischemic burden.
It has previously been proposed that high-resolution
perfusion quantification could be more sensitive for the
diagnosis of microvascular ischemia by avoiding spatial
averaging of the data or arbitrary assumptions on the
distribution of ischemia [12]. To the best of our know-
ledge however, our study is the first presenting a com-
parison between ischemic burden measurements
obtained by segmental and high-resolution approaches
and demonstrating evidence for this assumption. Previ-
ous reports based their results on subsegmental ROIs
drawn on perfusion maps and no results were given in
terms of ischemic burden or comparison between seg-
mental and high-resolution perfusion analysis [12]. Our
results demonstrate that high-resolution quantitative
perfusion assessment is more sensitive than segmental
quantification both in terms of MPR (Fig. 3) and ische-
mic burden (Fig. 4), providing differentiation between
segments with different combinations of LGE and visual
perfusion abnormalities. No significant differences be-
tween high-resolution and segmental MPR results were
observed for normal segments (PERF-LGE-), where less
MPR variability would be expected.
The presence of LGE related perfusion abnormalities
at rest in patients with HCM is well described in the lit-
erature [16–19]. An effect of scar on perfusion results is
also expected from histologic studies that have shown
that a reduction of vascularity is associated with scar
[37–39]. While an association between microvascular
dysfunction and LGE has been shown before [10], spe-
cific interaction between overt LV scar and high-
resolution perfusion quantification has not previously
been investigated. Our results demonstrate for the first
time the potential confounding effect of LGE on MPR
measurements. This finding is potentially of high rele-
vance, since previous reports suggesting an independent
role of “severe microvascular ischemia” in the prediction
of events have not taken into account the coexistence of
LV fibrosis and its potential interaction as covariate in
the risk prediction model. Indeed, “severe microvascular
ischemia” was defined in these studies as areas with ex-
tremely reduced MPR values ≤ 1.1 [7] or ≤1 [12]. How-
ever, adenosine mimics metabolic vasodilatation and a
degree of hyperemia is expected also in patients with
microvascular dysfunction, even though of reduced mag-
nitude in comparison with normal subjects. Therefore,
no areas of MPR < 1, suggestive of an opposite
hemodynamic effect, are expected, unless the presence
of LGE and a reduction of vascularity are taken into ac-
count. This is supported by our results, as areas with
MPR < 1 were also seen on our uncorrected high-
resolution MPR maps. However, these areas corre-
sponded almost entirely with areas of overt scar. Fig. 6
represents the relative MPR error caused by including
areas with severe fibrosis in the ischemic burden and
demonstrates that the majority of the error was intro-
duced for MPR values below 1. No further increase in
the relative MPR error was observed above MPR values
of 1.5, which has been shown before to correlate well in
patients with CAD with invasive reference standards for
the diagnosis of ischemia, such as FFR [40]. Therefore,
the described association between microvascular dys-
function and prognosis could be partially explained by
the coexistence of LV fibrosis, which is a known inde-
pendent predictor of risk [41].
The importance of accounting for LV scar in the as-
sessment of the ischemic burden is further supported by
the finding that almost one patient in three was re-
assigned to a lower tertile of ischemic burden as result
of the correction. (Fig. 7).
Another important finding of our study is that pa-
tients with LGE had larger ischemic burden in compari-
son with patients without LGE and that correction of
high-resolution perfusion maps by LV scar did not fully
eliminate this difference. This finding could be inter-
preted in a number of ways. It might indicate more se-
vere disease and microvascular dysfunction in patients
with LGE. It might also be explained by technical fac-
tors. We decided to correct high-resolution perfusion
maps for LV scar defined as regions with signal >6SD
above the average of remote normal tissue. Selecting
lower thresholds would result in the exclusion of larger
areas of fibrotic myocardium and in a smaller differ-
ence between LGE- and LGE+ patients. Given the com-
plexity of histological validation on significant number
of cases, we feel that this should be evaluated against
outcomes in future studies. Corrected ischemic burden
results proved in the current study to have a good re-
producibility when LGE was quantified by different
operators.
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Limitations of the study
This study enrolled a limited number of patients referred
on clinical grounds. The prevalence of perfusion abnor-
malities therefore does not represent the entire popula-
tion of patient with HCM but rather a group of patients
with HCM and suspected microvascular angina. None of
the patients included in this study had severe hyper-
trophy (>30 mm) and therefore we cannot comment on
the effect of fibrosis correction in this subgroup.
Conclusion
This study demonstrates the feasibility of combined
high-resolution fibrosis and perfusion quantification and
the potential of this method to provide more accurate
information on the ischemic burden. Further studies are
awaited regarding the impact of this novel approach on
risk stratification.
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